Nav: Home

'Good' cholesterol counters atherosclerosis in mice with diabetes

September 30, 2019

Increasing levels of a simplified version of "good" cholesterol reversed disease in the blood vessels of mice with diabetes, a new study finds.

Published online in the journal Circulation on September 30, the study results revolve around atherosclerosis, a condition where high levels of cholesterol cause "plaques" to form in vessel walls, eventually restricting blood flow to cause heart attacks and strokes. Many of these same patients have diabetes, in which tissues are injured by high blood sugar.

Led by researchers from NYU School of Medicine, this study provides the "first direct evidence" that raising levels of a simple, functional version of good cholesterol - the HDL protein shuttle that pulls cholesterol out of cells - reversed the progression of atherosclerosis in mice with diabetes.

The results, say the study authors, reflect the emerging view that HDL's ability to extract cholesterol from cells reduces inflammation, the immune reaction in which cells rush to injury sites. Part of the natural process that repairs damaged tissues, inflammation worsens disease in the wrong place (e.g. plaques).

"Our study results argue that raising levels of functional good cholesterol addresses inflammatory roots of atherosclerosis driven by cholesterol buildup beyond what existing drugs can achieve," says study senior author Edward Fisher, MD, PhD, the Leon H. Charney Professor of Cardiovascular Medicine at NYU Langone Health. "Good cholesterol is back as therapeutic target because we now understand its biology well enough to change it in ways that lower disease risk."

Better Measures

Treatments for atherosclerosis for decades have focused on lowering blood levels of LDL or "bad cholesterol," a second shuttle that delivers molecules of cholesterol from the diet (and from the liver) to the body's cells, including those in vessel walls. But the ability of treatments that lower LDL cholesterol to reduce heart attack risk is limited, and especially in adults with diabetes, who are twice as likely to die from heart disease or stroke as people without diabetes, according to the American Heart Association.

To reduce disease risk not addressed by lowering bad cholesterol, the field designed drugs that raised levels of the "good" cholesterol (HDL) shuttle that carts cholesterol from blood vessel walls to the liver for expulsion from the body. The two mechanisms should work together, but much anticipated HDL-raising drugs (e.g. cholesteryl ester transfer protein inhibitors) failed in 2016 clinical trials to reduce the risk of heart attacks beyond what could be accomplished by cholesterol lowering.

Faced with these limits, researchers looked more closely at the roles in atherosclerosis and diabetes of inflammation. Part of this shift was the realization that old measures for how a given "HDL-raising drug" countered disease - like how much of the HDL shuttle was in a person's bloodstream (HDL-C) - needed to be replaced. The new measure, says Fisher, should be how well a person's HDL can pull cholesterol out of cells (total cholesterol efflux), because it better captures the inflammatory part of the disease process.

The new measure builds on the discovery that signaling proteins and fats related to high blood sugar attach to, lower the number of, and disable HDL - which is composed of a protein called apolipoprotein A-I (apoA-I) linked to phospholipids. This lowers supplies of the shuttle capable of achieving cholesterol efflux, termed "functional HDL."

In sets of experiments, the current study authors raised functional HDL levels in diabetic mice by increasing the amounts apoA-I present, either by genetic engineering or direct injection. They found that the increase in functional HDL stopped cholesterol-driven immune cell multiplication (proliferation) in bone marrow, reduced inflammation in immune cells in plaques by half, and enhanced the reversal of atherosclerotic disease processes (regression) by 30 percent in mice already treated to lower their bad cholesterol.

Finally, the study results also show that increased HDL levels kept another set of immune cells called neutrophils from giving off webs of fibers that increase inflammation and blot clot formation in atherosclerosis, further blocking blood flow.

"For the study we built our own version of the HDL particle, called reconstituted HDL, which promises to become the basis for new kinds of functional HDL treatments that finally reduce the residual risk for cardiovascular disease not addressed currently," says first author Tessa Barrett, PhD, research assistant professor in the Department of Medicine at NYU School of Medicine.
-end-
Along with Fisher and Barrett, study authors from the Division of Cardiology at the NYU School of Medicine were Emilie Distel, Michael Garshick, Yoscar Ogando; along with Jiyuan Hu in the Division of Biostatistics, Jeffrey Berger in the Divisions of Cardiology and Hematology, and Ira Goldberg, in the Division of Endocrinology, Diabetes, and Metabolism. Also study authors were Andrew Murphy in the Division of Immunometabolism at Baker Heart and Diabetes Institute in Melbourne, Australia; Jianhua Liu in the Department of Surgery at Mount Sinai School of Medicine, and Tomas Vaisar and Jay Heinecke, in the Division of Metabolism, Endocrinology, and Nutrition at the University of Washington School of Medicine in Seattle.

Funding for the study was provided by NIH Grants R01 DK095684, R01 HL117226, R01 2 HL084312, PO1 HL092969, P01HL131481, and R01 HL114978; American Heart Association grants 18CDA34110203AHA, and 18CDA34080540), and by National Health and Medical Research Council (Australia) grants APP1083138, APP1106154, as well as a National Heart Foundation (Australia) 100440).

NYU Langone Health / NYU School of Medicine

Related Diabetes Articles:

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.
Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.
Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).
Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.
People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.
Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.
New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes
A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.
Can continuous glucose monitoring improve diabetes control in patients with type 1 diabetes who inject insulin
Two studies in the Jan. 24/31 issue of JAMA find that use of a sensor implanted under the skin that continuously monitors glucose levels resulted in improved levels in patients with type 1 diabetes who inject insulin multiple times a day, compared to conventional treatment.
Complications of type 2 diabetes affect quality of life, care can lead to diabetes burnout
T2D Lifestyle, a national survey by Health Union of more than 400 individuals experiencing type 2 diabetes (T2D), reveals that patients not only struggle with commonly understood complications, but also numerous lesser known ones that people do not associate with diabetes.
A better way to predict diabetes
An international team of researchers has discovered a simple, accurate new way to predict which women with gestational diabetes will develop type 2 diabetes after delivery.
More Diabetes News and Diabetes Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.